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High-yielding 18F radiosynthesis of a novel oxytocin
receptor tracer, a probe for nose-to-brain oxytocin
uptake in vivo†
Rhiannon Beard, *a Nisha Singh,bc Christophe Grundschober, d
Antony D. Gee *b and Edward W. Tate *a
A novel Al18F labelled peptide tracer for PET imaging of oxytocin
receptor has been accessed through a high radiochemical yield
approach. This tracer showed comparable aﬃnity and higher selectivity
and stability compared to oxytocin, andwas used to demonstrate direct
nose-to-brain uptake following intranasal administration, a common
yet controversial delivery route for oxytocin-based therapeutics.
The oxytocin (OT) system comprises the peptide hormone OT
and the transmembrane G-protein coupled oxytocin receptor
(OTR), which is expressed in organs including the uterus, heart,
kidney and brain. OT, the endogenous ligand of OTR, is
produced within the hypothalamus and stored in the posterior
pituitary gland until release after stimulation such as hugging,
breast-feeding and sexual intercourse.1 Consequently, OT has
been termed the ‘‘love hormone’’, as it facilitates reproduction
at all levels. More recently, the putative role of OT in modulation
of complex neuropsychiatric disorders including autism spectrum
disorders (ASD) and schizophrenia where it has undergone inves-
tigation as a therapeutic, has been the subject of considerable
controversy.2–4 In one study, mice with a mutation in Cntnap2,
which in humans leads to autistic spectrum disorders, experi-
enced social deficits and lower levels of brain OT. Interestingly,
daily treatment with OT reversed behavioural deficits.3 Further,
studies in humans have shown positive effects for treatment of
core symptoms of ASD when OT is administered intravenously
(i.v.).4 However, the blood–brain barrier severely restricts circulating
OT from crossing into the central nervous system, limiting
translation of basic OT research into effective and much
needed treatment solutions for behavioural disorders.
Intranasal (i.n.) administration oﬀers the potential for non-
invasive central nervous system delivery in a direct nose-to-brain
fashion.5 Multiple reports suggest acute OT administration aﬀects
social behaviours when given as a nasal spray in humans.6,7
However, clinical trials that study the prolonged administration
of OT have failed to demonstrate any clear therapeutic benefit by
various clinical endpoints.8,9 The mechanism of putative OT nose-
to-brain delivery is poorly understood, but is conjectured to occur
either directly through olfactory and nerve fibre routes, or indirectly
via absorption into blood capillaries.5,10 Currently no studies have
quantified brain uptake or distribution of OT after i.n. administra-
tion, since measurements of this kind are typically invasive. We
considered that a functional in vivo OTR positron emission tomo-
graphy (PET) tracer could provide a useful biological tool for
mapping OTR expression and enable a sensitive, non-invasive route
to quantify brain uptake and distribution via i.n. administration of
OT-based therapeutics.
18F (T1/2 100 min, b+ 0.635 MeV 97%) is the most frequently
used isotope for PET owing to its almost ideal imaging properties,
including low positron energy, an extended half-life and lack of side
emissions. Fluoride labelling strategiesmost widely applied for PET
tracer synthesis of biomolecules use nucleophilic or electrophilic
chemistries to attach 18F to carbon as a ‘‘prosthetic group’’, with
these reagents requiring prior synthesis. In contrast, direct radio-
labelling significantly simplifies and shortens radiosynthesis by
late-stage incorporation of 18F,11 for example using NODA-derived
chelation cages to irreversibly bind Al18F in high yield.12,13 The
core architecture of our tracer was design to maintain selective
receptor binding while allowing direct [18F]AlF labelling (Fig. 1A–D).
Consequently the tracer core was based on dLVT, an OT analogue
shown to accommodate large groups on position 8 whilst
retaining affinity and receptor selectivity (Fig. 1B).14,15 The
dLVT peptide architecture was produced using automated
Fmoc-synthesis incorporating a protected deaminated cysteine
residue (dC) in the final position (ESI,† Scheme S1), reported to
enhance OT stability in vivo.16,17 Orthogonal deprotection of the
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lysine 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl (ivdde)
allowed NODA conjugation on solid support via a methylphenyl-
acetic acid (MPAA) linker. Following conjugation, full deprotection
and cleavage from the resin afforded crude peptide which was
purified by RP-LCMS. Cyclisation was performed through DMSO-
mediated oxidation, affording final product in 22% overall yield. To
enable molar activity and Ki determination, cold (non-radioactive)
AlF-NODA-dLVT was also synthesised, alongside a library of OT
peptide analogues (Table 1) to determine a structure–activity
relationship (SAR) for OTR binding. Full sequences for these
peptides can be found in ESI,† Table S1.
Development of a highly specific ligand for OTR is challenging
since endogenous OT and arginine vasopressin (AVP) peptides
and their corresponding receptors share a related structure. OT
analogues thus have the potential to bind to multiple members
of the OT/AVP receptor family comprising the OTR and three
AVP receptor subtypes, and therefore we determined AlF-NODA-
dLVT’s binding profile across these potential targets.
OT analogues were screened in scintillation proximity assays
that displace [3H]OT or [3H]AVP from the corresponding receptors.
All peptides screened, including in a reduced state, preferentially
bound human OTR with nanomolar aﬃnity (Table 1). In line with
previous studies, conjugation of a large group to position 8 aﬀorded
analogues with increased selectivity and improved aﬃnity towards
OTR15 (approximately 60-fold for AlF-NODA-dLVT, and 7-fold for
dLVT; Table 1 and ESI,† Fig. S1). AlF-NODA-dLVT also demon-
strated enhanced selectivity (approximately 60-fold) towards OTR
compared to natural OT (approximately 16-fold). Remarkably,
selectivity was improved when the tracer was in a reduced state
(4240-fold), with similar aﬃnity towards the OTR.
Encouraged by these results, a radiofluorination method for
the preparation of [18F]AlF-NODA-dLVT was investigated. In the
course of developing this reaction we identified a substantial
loss of activity during concentration of the radionuclide. Following
the reported procedure, [18F]fluoride is trapped on an anion
exchange resin preconditioned with sodium acetate buﬀer, and
18F is concentrated into 100 mL fractions through elution with
saline, at an optimal pH for subsequent peptide labelling.13
Under these conditions, 0.9% saline produced a broad Na18F
elution profile (Fig. 2A).
Consequently only 53  3% Na18F was isolated in the highest
activity fraction. To overcome this loss, we narrowed the elution
profile using higher saline concentration, and found that 20%
saline increased isolation yields, allowing 76  5% of total
18F activity to be eluted in the highest activity fraction (Fig. 2A).
These values are improved over previous reports that compensate
for this loss by eluting Na18F in larger volumes from 2-fold13 to
5-fold.18 Dilution limits the activity used for radiolabelling
since peptide concentration heavily influences RCY, resulting
in overall RCY of 8.2% (from end of bombardment (EOB)),
despite high radionuclide incorporation and purification
(86%).18 In further optimisation experiments, radiolabelling
was performed following 18F elution with the highest activity
fraction eluted with either 0.9% or 20% saline, and with various
molar equivalents of AlCl3 compared to peptide precursor. 20%
saline consistently improved radiochemical conversion (RCC)
compared to 0.9% saline under analogous conditions (Fig. 2B
and C and ESI,† Fig. S2). For example, with 10 nmol aluminium
chloride a 1.5-fold increase in RCC of [18F]AlF-NODA-dLVT was
observed with 20% saline (Fig. 2C). These yields are similar to
those obtained when organic co-solvent is added to the
mixture,19,20 and may oﬀer an alternative method when DMSO
or MeOH is not suitable for the precursor, for example for
peptides sensitive to oxidation and for larger biomolecules.
This marked improvement was translatable to an unrelated
model peptide, NODA-GFAG, although the improvement in
RCC was less pronounced (ESI,† Fig. S3). Increased molar ratios
of aluminium chloride to peptide gave higher conversion for
[18F]AlF-NODA-dLVT, however, we found that lower concentrations
of aluminium chloride were preferred to yield higher molar
radioactivity in the isolated tracer; 60 nmol of aluminium
chloride (1 : 1.2 aluminium chloride : peptide molar ratio)
aﬀorded [18F]AlF-NODA-dLVT in RCC of 90  3% with a molar
Fig. 1 Structure of OT (A), dLVT (B), OTR tracer precursor NODA-dLVT (C),
and 18F radiolabelled tracer (D). Peptides contain a cyclic configuration due to
the disulphide bond between positions 1 and 6. Key: dC= deaminated cysteine.
Table 1 Ki values (nM) of OT and peptide analogues for human OTR and
vasopressin receptors
Peptide OTR V1a V1b V2
OTc 1.2  0.3 20  3 46000 46000
dOTc 1.6  1.3 388  157 nd 46000
dOToc 1.2  0.9 362  124 nd 46000
dLVTc 3.4  1.0 24  5 nd 4844  1670
dLVToc 6.3  3.6 31  9 nd 5819  1704
AlF-NODA-dLVTc 2.6  1.7 157  26 46000 46000
AlF-NODA-dLVToc 3.3  1.5 821  217 nd 46000
Values represent mean values of four diﬀerent experiments, each performed
in duplicate, with standard deviation. Key: c = cyclised; oc = open chain;
OTR = oxytocin receptor.
Fig. 2 Optimisation of 18F radiolabelling of NODA-dLVT. (A) Elution
profile of [18F]NaF with 0.9% (dashed) or 20% (solid) saline from anion
exchange resin in 100 mL fractions, mean of 5 samples for each condition.
Radiochemical conversion (RCC) for [18F]AlF labelling of NODA-dLVT
(72 nmol) using 0.9% (B) or 20% (C) saline with diﬀerent molar equivalents of
aluminium chloride at 105 1C for 15 min. Values represent mean of 3 samples.
Communication ChemComm
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
5 
Ju
ly
 2
01
8.
 D
ow
nl
oa
de
d 
on
 7
/5
/2
01
8 
4:
34
:1
2 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2018 Chem. Commun.
radioactivity of 39  12 GBq mmol1, whereas 20 nmol
(i.e. 1 : 3.6 aluminium chloride : peptide) aﬀorded the tracer in
71 5% RCC, but with a molar activity of 66  8% GBq mmol1.
Using optimised conditions, [18F]AlF-NODA-dLVT was synthe-
sised reproducibly and formulated within 70 min, with isolated
RCY of 36% (decay corrected, from EOB), radiochemical purity
(RCP) Z 95% and molar activity Z 58 GBq mmol1 (ESI,†
Fig. S4). Notably, the RCY reported here is significantly improved
from previous reports using a similar labelling approach, which
range from 8.2–24% (from EOB).18,20–22
To justify use of [Al18F]NODA-dLVT in vivo, tracer lipophilicity
and specific binding were determined through a standard shake
flask assay and rat brain autoradiography, respectively. A logD7.4
of 0.54  0.1 was established for [Al18F]NODA-dLVT indicating
a hydrophilic profile and potential for low non-specific binding.
To investigate the feasibility of [Al18F]NODA-dLVT for nervous
system imaging, tracer was incubated at a concentration of
3 nM, either alone or in the presence of excess OT (10 mM) with
brain tissue cut in the sagittal plane to determine total vs. non-
specific binding (Fig. 3). This enabled calculation of % specific
binding of [Al18F]NODA-dLVT to regions of brain tissue (ESI,†
Section 4.2). [18F]AlF-NODA-dLVT specifically bound regions
known to express appreciable levels of OTR (Fig. 3),23–26 including
hippocampus (CA1: 53  4%; subiculum, S: 60  1%), central
amygdala nucleus (ac: 56  1%), olfactory systems (olfactory
tubercle, Tu: 53  5%; anterior olfactory nucleus, AO: 38  2%),
acumens nuclei (Acb: 43  4%), and cortical regions (visual cortex,
V1: 61  4%; motor cortex, MC: 42  4%).
To investigate the plausibility of i.n. administration for
OT-like therapies, given the similar structure and hydrophilic
profile between AlF-NODA-dLVT and OT, in vivo tissue distribu-
tion of [18F]AlF-NODA-dLVT was determined following i.n. or
i.v. administration. Since OT is rapidly degraded following i.v.
injection (plasma half-life approximately 3 min),16 the systemic
plasma half-life of AlF-NODA-dLVT was first determined after
i.v. bolus (ESI,† Fig. S5). AlF-NODA-dLVT had an approximately
5-fold increase in half-life compared to OT (14 min vs. 3 min),
and time-points of 10 min and 30 min were thus selected for i.v.
and i.n. administration routes, respectively. Here, it is anticipated
that both routes show independent kinetic and metabolic
profiles and the extended apparent availability of OT following
i.n. administration supports a longer timeframe for this study.27,28
Distribution was determined through gamma counting of radio-
activity in isolated tissue. A large portion underwent excretion via
kidneys (i.v. 4.6 0.4%ID per g; i.n. 1.31 0.7%ID per g) and urine
(i.v. 2.5  1.2%ID per g; i.n. 7.7  2.2%ID per g), as expected from
the hydrophilic character of the tracer, similar to previous results
found with radiolabelled OT given i.v. (Fig. 4A).29
[18F]AlF-NODA-dLVT uptake in brain parenchyma was increased
by i.n. administration, however exposure remained low (i.v. 0.05 
0.03%ID per g; i.n. 0.11  0.03%ID per g, P = 0.044; Fig. 4B), which
was mirrored in nanoPET scans over the course of 1.5 h (ESI,†
Fig. S6). Accounting for plasma volume contributions from the
5.2% of the brain assumed to be capillaries, the brain permeable
material in this study is approximately 4.7  102%ID per g by
i.v. administration.30 A significant proportion was detected in
the olfactory bulb following i.n. administration compared to the
i.v. route (i.n. 2.30  1.8 cf. i.v. 0.05  0.02%ID per g, P = 0.026),
implying nose-to-brain uptake via nerve fibres, as opposed to blood-
to-brain transfer from indirect diﬀusion into the bloodstream.31,32 In
addition, a large portion was detected in the cerebellum following
i.n. administration in relation to parenchyma uptake (i.n. 0.31 
0.26; 2.8-fold cf. i.v. 0.05  0.01%ID per g; 1.1-fold).
In summary, we have developed a novel OTR tracer NODA-
dLVT radiolabelled with Al18F, that binds OTR with nanomolar
aﬃnity, and exhibits an enhanced selectivity profile compared to OT
in both oxidised and reduced states. During the radiosynthesis, we
incorporated an improved methodology for aqueous 18F fluoride
recovery which significantly enhances RCY, and is likely to be widely
applicable to other radiotracers. [18F]AlF-NODA-dLVT administered
by i.n. and i.v. routes demonstrated low brain parenchyma uptake.
Yet, i.n. administration gave a significant signal in the olfactory
bulbs suggesting ‘‘direct nose-to-brain’’ uptake. However, it is
important to note that the tracer was unable to penetrate
Fig. 3 Specific binding profile of [18F]AlF-NODA-dLVT. Radiograms of
total (top; 3 nM [18F]AlF-NODA-dLVT) and nonspecific binding (bottom;
3 nM [18F]AlF-NODA-dLVT and 10 mM OT) of [18F]AlF-NODA-dLVT to rat
brain slices in the sagittal pane. Areas with high specific binding are
indicated on the figure with arrow heads. Key: AO = anterior olfactory
nucleus; CA1 = field CA1 of the hippocampus; Acb = accumbens nuclei;
Tu = olfactory tubercle; VMH = ventromedial hypothalamic nuclei; MC =
motor cortex; V1 = primary visual cortex; S = subiculum; ac = central
amygdala nucleus; lo = lateral olfactory tract.
Fig. 4 Biodistribution of [18F]AlF-NODA-dLVT in rat. (A) Shows biodistribution
in major peripheral organs, while (B) shows uptake of [18F]AlF-NODA-dLVT in
central nervous system regions. Both are shown relative to blood levels
following either i.n. (30 min) or i.v. (10 min) administration. Each data point
corresponds to mean  SD, n = 3.
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deeper regions of brain tissue for specific binding during
the timescale studied. Consequently, our findings suggest
that the i.n. route is not significantly more eﬃcient than i.v.
for OT-based tracers. While i.n. administration lead to modest
parenchyma delivery, this increase may be relevant for changes
in behavioural and neural responses, as suggested in other studies.
In addition, the presence of radioactivity in the cerebellum may
suggest peptide degradation following absorption, and improve-
ment in the stability and selectivity of OT agonists may prove
beneficial for clinical eﬃcacy.
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